Abstract
The relationship between plasma interleukin-6 (IL-6) concentration and its soluble receptor in Crohn’s disease (CD) is not well elucidated. Twenty healthy volunteers and 94 consecutive patients with CD (44 in relapse and 50 in remission) were studied. Plasma IL-6 concentrations in patients with active disease [80 ± 9 pg/ml; mean ± standard error of the mean (SEM)] were significantly higher than in patients with inactive disease (50 ± 4 pg/ml; P < 0.001) or controls (3 ± 1 pg/ml; P < 0.001). However, concentrations did not vary with the severity of CD attacks. Plasma concentrations of soluble interleukin-6 receptor (sIL-6R) in active-CD patients (77 ± 5 ng/ml) did not differ significantly from those with inactive disease (82 ± 5 ng/ml), while both groups had significantly raised concentrations compared with those of controls (58 ± 6 ng/ml; P < 0.03 and P < 0.01, respectively). Plasma IL-6 concentrations correlated significantly with serum C-reactive protein (CRP) (r = 0.34; P < 0.001), whereas plasma sIL-6R concentrations did not. Taken together, these data suggest that, although IL6 and sIL6-R are both involved in the inflammatory process of CD, they are poor markers of disease activity.
Similar content being viewed by others
Abbreviations
- APP:
-
Acute-phase protein
- CD:
-
Crohn’s disease
- ELIA:
-
Enzyme–ligand immunoassay
- ELISA:
-
Enzyme-linked immunosorbent assay
- ESR:
-
Erythrocyte sedimentation rate
- IL-6:
-
Interleukin-6
- IL-6R:
-
Interleukin-6 receptor
- sIL-6R:
-
Soluble interleukin-6 receptor
- 5-ASA:
-
5-aminosalicylate acid
- GMCSF:
-
Granulocyte macrophage colony stimulating factor
- HSF:
-
Hepatocyte stimulating factor
- LIF/HILDA:
-
Leukemia inhibitory factor/Human interleukin for DA cells
References
Akira S, Taga T, Kishimoto T (1993) Interleukin 6 in biology and medicine. Adv Immunol 54:1–78
Kishimoto T, Akira S, Taga T (1992) Interleukin 6 and its receptor: a paradigm for cytokines. Science 258:593–597
Lobo AJ, Evans SW, Jones SC, Banks R, Rathbone BJ, Axon ATR, Whitcher JT (1992) Plasma interleukin 6 in inflammatory bowel disease. Eur J Gastroenterol Hepatol 4:367–372
Mahida YR, Kurbac A, Gallagher A, Hawkey CJ (1991) High circulating concentrations of interleukin 6 in active Crohn’s disease but not ulcerative colitis. Gut 32:1531–1534
Suzuki H, Yasukawa K, Saito T, Narasaki M, Hasegawa A, Taga T (1993) Serum soluble interleukin 6 receptor in MRL/pr mice is elevated with age and mediates the interleukin 6 signal. Eur J Immunol 23:1078–1082
Mackiewics A, Wiznerowicz M, Roeb E, Karczewska A, Nowak J, Heinrich PC, et al. (1995) Soluble interleukin-6 receptor is biologically active in vivo. Cytokine 7:142–149
Gaillard JP, Bataille R, Brailly H, Zuber C, Yasakawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B (1993) Increased and highly stable levels of functional soluble interleukin 6 receptor in sera of patients with monoclonal gammapathy. Eur J Immunol 23:820–824
Montero-Julian FA, Liautard J, Flavetta S, Romagne F, Gaillard JP, Brochier J, Klein B, Brailly H (1994) Immunoassay for functional human soluble interleukin 6 receptor in plasma based on ligands/receptor interactions. J Immunol Methods 169:111–121
Bernades P, Heckeitsweiler P, Benozio M, Descos L, Geffroy Y, Hemet J, Loygue J, Modigliani R, Potet F, Weill JP (1978) Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn’s disease and rectocolitis): a cooperative study by the Cryptogenic Enterocolitis Study Group). Gastroenterol Clin Biol 2:1047–1054
Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s disease activity. Lancet 1:514
Hyams JS, Fitzgerald JE, Treem WR, Wyzga N, Kreutzer DL (1993) Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 104:1285–1292
Gross V, Andus T, Caesar I, Roth M, Schölmerich J (1992) Evidence for continuous stimulation of interleukin 6 production in Crohn’s disease. Gastroenterology 102:514–519
Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Deviere J, Franchimont D (2005) Profile of soluble cytokine receptors in Crohn’s disease. Gut 54:488–495
Chirmule N, Oyaizu N, Kalyanaraman VS, Pahwa S (1991) Misinterpretation of results of cytokine bioassays. J Immunol Methods 137:141–144
Burger R, Gramatzki M (1993) Responsiveness of interleukin 6 dependent cell line B9 to IL-11. J Immunol Methods 158:147–148
Barton BE, Jackson JV, Lee F, Wagner J (1994) Oncostatin M stimulates proliferation in B9 hybridoma cells. Potential role of oncostatin M in plasmacytoma development. Cytokine 6:147–153
May LT, Viguet H, Kenney JS, Ida N, Allison AC, Sehgal PB (1989) High levels of complexed interleukin-6 in human blood. J Immunol 142:148–152
Matsuda T, Hirano T, Nagasawa S, Kishimoto T (1989) Identification of α2 macroglobulin as a carrier protein for interleukin 6. J Immunol 142:148–152
Hosokawa T, Kusugami K, Ina K, Ando T, Shinoda M, Imada A, Ohsuga M, Sakai T, Matsuura T, Ito K, Kaneshiro K (1999) Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J Gastroenterol Hepatol 14:987–996
Bienvenu J, Coulon L, Doche C, Gutowski MC, Grau GE (1993) Analytical performances of commercial ELISA kits for IL-2, IL-6 and TNFα: a WHO study. Eur Cytokine Netw 4:447–451
Zohlnofer D, Graeve L, Rose-John S, Schooltink H, Dittrich E, Heinrich PC (1992) The hepatic interleukin 6 receptor. Down regulation of interleukin 6 binding sub-unit (gp 80) by its ligand. FEBS Lett 306:219–222
Ishibashi T, Kimura H, Shikawa Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y (1989) Interleukin 6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241–1244
Suematsu S, Matsuda T, Aozasa K, Akira S, Nakao N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmocytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci U S A 86:7447–7451
Hollen CW, Henthorm J, Koziol JA, Burstein SA (1991) Elevated serum interleukin 6 levels in patients with reactive thrombocystosis. Br J Haematol 79:286–290
Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsurata O, Harada K, Tateishi H, Nishiyama T, Tanikawa K (1995) Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36:45–49
Louis E, Belaiche J, Van Kemseke C, Franchimont D, De Groote D, Gueenen V, Mary JY (1997) A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn’s disease. Eur J Gastroenterol Hepatol 9:939–944
Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF (2000) Blockade of interleukin 6 trans signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn’s disease and experimental colitis in vivo. Nat Med 6:583–588
Taga T, Hibi M, Hirata Y, Yamazaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130. Cell 58:573–581
Saito M, Yoshida K, Hibi M, Taga T, Kishimoto T (1992) Molecular cloning of a murine IL-6 receptor associated signal transducer, gp 130, and its regulated expression in vivo. J Immunol 148:4066–4071
Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T (1988) Cloning and expression of the human interleukin 6 (BSF 2/IFN beta 2) receptor. Science 241:825–828
Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human Il 6 receptor/IL6 up-regulates expression of acute phase proteins. J Immunol 149:2021–2027
Vinck A, Coulie PG, Warnier G, Renauld JC, Stevens M, Donckers P, Van Snick J (1990) Mouse plasmocytoma growth in vivo: enhancement by interleukin-6 and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med 172:997–1000
Suzuki H, Yasukawa K, Saito T, Anzai M, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T (1992) Antihuman interleukin 6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22:1989–1993
Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Brief report: alleviation of systemic manifestations of Casteman’s disease by monoclonal anti interleukin 6 antibody. N Engl J Med 330:602–605
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nancey, S., Hamzaoui, N., Moussata, D. et al. Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn’s Disease Activity. Dig Dis Sci 53, 242–247 (2008). https://doi.org/10.1007/s10620-007-9849-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-007-9849-6